At a glance
- BAM-15 is not an FDA-approved drug: Drugs@FDA has no record of it.
- PubMed lists 73 publications mentioning it, including 0 randomized controlled trials and 31 animal-only studies.
- No study registered on ClinicalTrials.gov tests it as an intervention.
- FDA’s adverse event system (FAERS) has no reports mentioning it.
Research topics
Most frequent MeSH subject headings in the latest PubMed records (English, as indexed).
Regulatory status
Drugs@FDA applications
No application found in Drugs@FDA, FDA's database of approved drugs.
Source: Drugs@FDA (openFDA) · verified October 30, 2026 · API query
FDA compounding safety list
Not on FDA's list of bulk drug substances that may present significant safety risks in compounding.
Source: FDA.gov — Category 2 bulk drug substances · verified October 30, 2026
Removal of a substance from a regulatory list does not mean it has been approved. A "research use only" label does not make a product safe or legal for human use.
Scientific publications
Counts are PubMed records that mention the peptide in the title or abstract. Categories overlap, and a mention is not the same as testing the peptide as a treatment. Each number opens the exact PubMed search. Effects seen in laboratory or animal studies may not occur in humans. A registered clinical trial does not show that a substance is effective or safe.
Latest publications
- A Dissociation-Based Seahorse XF Workflow for Quantifying Averaged Bioenergetics in Anchorage-Independent Cancer Cell Clusters.
- BAM15 Enhances Regorafenib Cytotoxicity in a Canine Osteosarcoma Cell Model.
- A Programmed Drug-Loaded and Penetration-Delivery Functionalized Microneedle Patch for Synergistic Obesity Treatment.
- Mitochondrial uncoupler BAM15 attenuates cryopreservation-induced damage in human sperm by stabilizing mitochondrial homeostasis†.
- FUNDC1-Associated Regulation of Mitochondrial Function Is Crucial for Preventing Endothelial Injury in Hyperglycemia.
- BAM15 improves oocyte quality against obesity via PPARγ-dependent mitochondrial function.
- Targeting the energy metabolism of melanoma cells: FX-11 acts as a mitochondrial uncoupler.
- Mitochondrial uncoupling inhibits serine catabolism via FTO activation in metastatic breast cancer.
- Structure-activity relationship profiling of N-substituted 8-trifluoromethyl-9H-purin-6-amines as mitochondrial protonophores.
- BAM 15 Exerts Molluscicidal Effects on Pomacea canaliculata Through the Induction of Oxidative Stress, Impaired Energy Metabolism, and Tissue Damage.
Source: PubMed (NCBI) · verified October 30, 2026
Clinical trials
No registered study on ClinicalTrials.gov lists this peptide as an intervention.
Source: ClinicalTrials.gov · verified October 30, 2026
Adverse event reports
No FAERS reports mention this peptide.
Change history
No changes since monitoring began on October 30, 2026.